Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

Related Articles by Review for PubMed (Select 11344269)

1.

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T.

Proc Natl Acad Sci U S A. 2001 May 22;98(11):6500-5. Epub 2001 May 8.

2.

Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.

Fukumoto S, Yamashita T.

Curr Opin Nephrol Hypertens. 2002 Jul;11(4):385-9. Review.

PMID:
12105387
3.

Fibroblast growth factor 23 and its receptors.

Yu X, White KE.

Ther Apher Dial. 2005 Aug;9(4):308-12. Review.

PMID:
16076372
4.

FGF23 and disorders of phosphate homeostasis.

Yu X, White KE.

Cytokine Growth Factor Rev. 2005 Apr;16(2):221-32. Epub 2005 Feb 5. Review.

PMID:
15863037
6.
7.

FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.

Quarles LD.

Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E1-9. Review.

8.

Osteo-renal cross-talk and phosphate metabolism by the FGF23-Klotho system.

Ohnishi M, Razzaque MS.

Contrib Nephrol. 2013;180:1-13. doi: 10.1159/000346774. Epub 2013 May 3. Review.

PMID:
23652546
9.

Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.

Hu FK, Yuan F, Jiang CY, Lv DW, Mao BB, Zhang Q, Yuan ZQ, Wang Y.

Chin J Cancer. 2011 Nov;30(11):794-804. doi: 10.5732/cjc.011.10013. Review.

10.

[Disorders of phosphate metabolism].

Fukumoto S.

Rinsho Byori. 2010 Mar;58(3):225-31. Review. Japanese.

PMID:
20408440
11.

Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.

Gattineni J, Baum M.

Pediatr Nephrol. 2010 Apr;25(4):591-601. doi: 10.1007/s00467-009-1273-z. Epub 2009 Aug 11. Review.

12.

The wrickkened pathways of FGF23, MEPE and PHEX.

Rowe PS.

Crit Rev Oral Biol Med. 2004 Sep 1;15(5):264-81. Review.

14.

[Clinical aspect of recent progress in phosphate metabolism. The pathophysiology of diseases caused by aberrant actions of FGF23].

Shimizu Y, Fukumoto S.

Clin Calcium. 2009 Jun;19(6):802-7. doi: CliCa0906802807. Review. Japanese.

PMID:
19483274
15.

[FGF23-related hypophosphatemic rickets/osteomalacia].

Ito N, Fukumoto S.

Clin Calcium. 2007 Oct;17(10):1514-20. Review. Japanese.

PMID:
17906402
16.
17.

[Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia].

Kinoshita Y, Fukumoto S.

Clin Calcium. 2014 Aug;24(8):1217-22. doi: CliCa140812171222. Review. Japanese.

PMID:
25065874
18.

[Bone and joint diseases in children. Phosphaturic hormone, FGF23, and bone metabolism].

Ozono K.

Clin Calcium. 2010 Jun;20(6):896-903. doi: CliCa1006896903. Review. Japanese.

PMID:
20513948
19.

What have we learnt about the regulation of phosphate metabolism?

Blumsohn A.

Curr Opin Nephrol Hypertens. 2004 Jul;13(4):397-401. Review.

PMID:
15199289
20.

Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia.

Fukumoto S.

Endocrinol Metab (Seoul). 2014 Jun;29(2):136-43. doi: 10.3803/EnM.2014.29.2.136. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk